-
05.14.2024 Seikagaku Announces the Biologics License Application for SI-6603 Has Been Accepted for Filing by the U.S. FDA (141KB)
-
05.13.2024 Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (384KB)
読む Consolidated Financial Results for the Fiscal Year Ended March 31, 2024
-
05.13.2024 Seikagaku Announces Differences between Full-Year Consolidated Financial Forecasts (226KB)
読む Seikagaku Announces Differences between Full-Year Consolidated Financial Forecasts
-
02.14.2024 Consolidated Financial Results for the Third Quarter of Fiscal year 2023 (222KB)
読む Consolidated Financial Results for the Third Quarter of Fiscal year 2023
Seikagaku News Releases are issued to provide stakeholders with the most up-to-date information related to our company.
-
05.16.2024 Presentation Material for the Briefing on FY2023 Financial Results
読む Presentation Material for the Briefing on FY2023 Financial Results
-
05.13.2024 Seikagaku announced the financial results for the Fiscal Year ended March, 2024
読む Seikagaku announced the financial results for the Fiscal Year ended March, 2024
-
04.01.2024 Seikagaku will announce the financial results for the Fiscal Year ended March 31, 2024 at 16:00 on May 13, 2024
-
03.08.2024 Sustainability - External Evaluations